Deka Research and Development
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Deka Research and Development sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Deka Research and Development: 4 sponsored US clinical trials, 1 recruiting.
Deka Research and Development sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. The most-studied condition in this pipeline is Insulin Treated Type 2 Diabetes Mellitus, with 1 trials.
Upper-quartile sponsor footprint
Deka Research and Development sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Twiist Postmarket Surveillance Study for Type 1 Diabetes
NCT07356089
Innovative Automated Insulin Delivery System for Type 2 Diabetes
NCT06853990
An Open Label Study to Allow Patients Continuous Use of the HemoCare™ Hemodialysis System
NCT04198012
Study of HemoCare™ Hemodialysis System for Home Nocturnal Dialysis in Patients With ESRD
NCT04087213
Therapeutic Areas
What is open in the Deka Research and Development pipeline
1 recruiting of 4 indexed (25% open); 2 completed (50%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Insulin Treated Type 2 Diabetes Mellitus (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Deka Research and Development: open-pipeline peers nationwide
Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Deka Research and Development sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 25% open enrollment (± trial volume)
- AB Science · 25% recruiting · 8 trials
- Abbott Point of Care · 25% recruiting · 8 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
Related
What to do with this Deka Research and Development page
4 registered trials is a research-attention snapshot, not an endorsement of Deka Research and Development or any single study.
- 1 of Deka Research and Development's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Insulin Treated Type 2 Diabetes Mellitus is the condition Deka Research and Development studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Insulin Treated Type 2 Diabetes Mellitus trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Deka Research and Development pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.